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ABSTRACT OF THE THESIS 
 
Clinical Outcomes with Melanoma-Associated Antigen-A and Program-death ligand 1 
Expression in Urothelial Carcinoma 
 
 
by 
Izak Faiena 
Master of Science in Clinical Research  
University of California, Los Angeles, 2019 
Professor Robert M. Elashoff, Chair 
 
Abstract:  
Background:  The melanoma-associated antigen-A (MAGE-A) and program-death ligand 1 (PD-
L1) are present in urothelial carcinoma (UC). We aim to assess survival outcomes in patients with 
MAGE-A and PD-L1 expression. 
 
Methods: Analysis of MAGE-A and PD-L1 expression on neoplastic cells was conducted using 
tissue microarrays from patients with UC. We compared differential expression between stage and 
grade. Co-expression of MAGE-A and PD-L1 were sub-categorized. Fisher’s exact test was done 
for categorical variables followed by analysis of univariable and multivariable assessment of 
recurrence and progression free survival (RFS, PFS). 
 
 iii 
 
Results: Co-expression of MAGE+/PD-L1+ had a higher expression in advanced disease, however 
only MAGE+/PD-L1- group was associated with shorter RFS (HR 1.89, 95%CI 1.19-2.99; 
p=0.006). MAGE+/PD-L1+ was associated with the worst PFS (HR 17.1, 95%CI 5.96-49.4; 
p=<0.001). MAGE-A expression was more prevalent high-grade (p=0.015), and higher stage ≥pT2 
(p=0.001). The 5-year RFS in MAGE+ was 44%vs.58% for MAGE- samples. On multivariable 
analysis MP was also associated with shorter recurrence (HR 1.55, 95%CI 1.05-2.30; p=0.03). 
Similarly, MAGE+ was associated with shorter PFS (HR 3.12, 95%CI 1.12-8.68; p=0.03).  
 
Conclusion: We report that the expression of MAGE-A and PD-L1 is increased in more advanced 
disease and associated with shorter PFS. Furthermore, expression of MAGE-A is significant in 
higher grade and stage, and was associated with shorter RFS and PFS. The finding of worse 
prognosis of MAGE-A/PD-L1 provides early evidence that a potential combinatorial treatment 
strategy of co-targeting MAGE/PD-L1 with respective agents might be feasible. Further studies 
are needed to validate these findings.  
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Body Text 
1. Introduction 
The MAGE-A gene family consists of 12 MAGE-A genes located on chromosome Xq28.  The 
function and biological role of MAGE-A proteins in cancer have not been completely elucidated; 
however, members of MAGE-A have been implicated in modulating the activity of E3 ubiquitin 
ligases on targets related to apoptosis and in the suppression of p53-dependent apoptosis. [1] 
MAGE has been a highly attractive target for cancer immunotherapy because of its broad 
representation in cancer tissues but restricted expression in normal adult tissues, namely, immune-
privileged germ cells.  Recent studies have shown significant expression of MAGE antigen in 
urothelial carcinoma (UC). [2-6]  This observation has clinical implications as other studies have 
shown a poor-prognosis in MAGE-positive patients. [6, 7] Currently, there are numerous 
approaches targeting this antigen in the clinical setting including vaccines, and adoptive T-cell 
therapy (TCR). A recent phase I trial using a TCR targeting MAGE-A has shown a potential 
benefit. [8] The safety of this TCR across multiple tumor types is currently being evaluated in a 
phase I trial (NCT03139370).  
 
The use of immune checkpoint inhibitors in UC has become an important salvage option with 
reasonable response rates for patients who progress on cytotoxic chemotherapy. [9] While MAGE-
A expression has been described in UC, evidence is lacking regarding the correlation of MAGE 
and PD-L1 expression in UC.  This data is of interest, as it informs a potential combinatorial 
therapeutic strategy using adoptive cell transfer together with a checkpoint inhibitor. It is widely 
recognized that the use of CAR-T cells in solid oncology will likely require combination therapy 
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to address an immunosuppressive tumor microenvironment, with checkpoint inhibitors, for 
example. [10] Some early data suggest that a combination approach may potentiate an immune 
response and enhance the efficacy of using adoptive cell therapy. [11-13] In addition, there are 
studies that suggest that receiving checkpoint inhibitors prior to tumor infiltrating lymphocytes 
(TIL) harvest may lead to more effective TIL harvest, with a shorter ex vivo expansion time, and 
increased efficacy. [14, 15] In this study, we aimed to assess the survival outcomes in patients with 
urothelial carcinoma and the correlation with MAGE and PD-L1 expression.  
 
2. Methods and Materials: 
2.1. Study population and outcomes 
 
The study cohort consisted of 422 UC samples in 275 patients from transurethral resection of 
bladder tumor or radical cystectomy done at a tertiary medical center between 1985 and 1998. 
Available clinical, pathological and follow-up data on each patient were obtained. The main 
covariates were age, gender, race, smoking history, cancer history, procedure, pathologic stage, 
and grade. The study outcomes were recurrence-free, progression-free survival in patients who 
underwent both RC and TURBT, and overall survival in patients who underwent RC only.  The 
overall aim was the association of both MAGE expression with survival outcomes as well as 
MAGE and PD-L1 expression with survival outcomes.  
 
2.2. Tissue microarray construction 
Tissue from formalin fixed, paraffin embedded specimens were obtained. Three 0.6 mm core 
biopsies were taken from representative tumor regions and precisely arrayed using a custom-built 
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instrument as previously described. [16] Sections of four microns of the tissue microarray block 
were transferred to glass slides using the paraffin sectioning aid system comprising adhesive 
coated PSA-CS4x slides, adhesive tape and an ultraviolet lamp (Instrumedics, Hackensack, New 
Jersey) to support the cohesion of 0.6 mm array elements. 
 
2.3. Immunohistochemical staining and evaluation 
 
IHC analysis of MAGE-1 (mouse clone 6C1, Thermo Scientific), and PD-L1 (rabbit clone SP142, 
Spring Biosciences) was performed at room temperature (RT) on the Dako Link Autostainer 48 
(Agilent, Santa Clara, CA). Tissue sections underwent pretreatment using Rip Tide, a proprietary 
antigen retrieval buffer (Mosaic Laboratories, Lake Forest, CA) for 40 minutes at 95°C. Once the 
Autostainer procedure was initiated, the slides were rinsed with buffer immediately and after each 
of the following steps: 1) incubation with Envision Peroxidase (Dako) for 5 minutes to quench 
endogenous peroxidase; 2) incubation with MAGE-1 antibody, PD-L1 antibody or isotype 
negative control for 30 minutes; 3) detection with Envision FLEX Linker for 15 minutes; 4) 
detection with Envision FLEX HRP for 20 minutes; and 5) staining with DAB (Dako) for 10 
minutes each. Upon completion of the staining procedure, slides were counterstained offline with 
hematoxylin (Dako) for 2 minutes, rinsed and coverslipped. 
 
Evaluation of IHC stains was performed by a pathologist who recorded the staining intensity, 
subcellular localization, and percentage of positively-stained tumor cells. Staining intensity was 
evaluated on a semi- quantitative scale with the percentage of cells staining at each of the following 
four levels recorded: 0 (unstained), 1+ (weak staining), 2+ (moderate staining) and 3+ (strong 
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staining). An H-Score was calculated based on the summation of the product of percent of cells 
stained at each intensity using the following equation: (3 x % cells staining at 3+) + (2 x % cells 
staining at 2+) + (1 x % cells staining at 1+).  The maximum staining intensity of normal adjacent 
tissue (NAT), endothelia, smooth muscle, fibroblasts, stroma, inflammatory cells, and nerve were 
recorded if observed. If positive PD-L1 staining was observed in endothelial cells, the percentage 
of staining was estimated.  MAGE positive (MP) status was defined as ≥50% positive staining 
with 2+ or 3+ intensity as compared with MAGE negative (MN), a cut-off that has been used 
previously in evaluating MAGE staining. [8] A commonly used PD-L1 cutoff criteria of ≥1% 
positive staining (PP) of tumor cells was applied. [17] 
 
2.4. Statistical analysis 
 
Descriptive statistics for study variables were computed for the overall cohort as well as for the 
MP and MN subgroups. Study variables were compared between these subgroups using the 
Wilcoxon rank-sum tests for continuous variables and Chi-square or Fisher’s exact tests for 
categorical variables. We further subdivided patients according to MAGE and PD-L1 staining 
status to assess the effect of co-expression on survival. Patients’ specimen-level data was the unit 
of analysis for recurrence, as biopsies were done at each recurrence thus reflecting this particular 
outcome with follow-up time calculated from procedure until event or censoring. However, 
patient-level data was used to assess progression-free survival and overall survival. Recurrence-
free survival curves were created with the Kaplan-Meier method and survival was compared 
between discrete MAGE and PD-L1 groups with the log-rank test. For recurrence, univariable and 
multivariable mixed-effects Cox proportional hazards model were used to evaluate predictors of 
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outcome, adjusting for repeated measurements per patient. Variables selected in the model were 
either significant on the unvariable and/or were felt to be clinically relevant. However, due to small 
number of events for progression, only a univariable analysis was conducted. Tests for 
proportionately were not violated in all models. Overall survival (OS) was analyzed only in 
patients who underwent radical cystectomy using Cox models. Performance of the Cox models 
was assessed using Harrell’s C statistic. [18] A sensitivity analysis was also performed to assess 
effect of year of treatment on overall survival. The institutional review board approval at our 
institution was obtained. Two-tailed p-values <0.05 were considered statistically significant. 
Statistical analyses were performed with Stata statistical software version 15 (StataCorp, College 
Station, TX). 
 
3. Results: 
3.1. Patient characteristics  
The patient cohort consisted of 275 patients and 422 samples (table 1 and 2). Median age was 70 
(IQR 62-76) with the majority of the cohort consisting of male, Caucasian patients.  A large 
proportion of patients were smokers or former smokers (54%). MAGE staining was associated 
with more advanced stage (≥pT2 52% vs. 42%), and high grade disease (73% vs. 60%; p=0.015). 
A similar trend was noted for PD-L1 positive samples, which were more likely being higher stage 
and grade, respectively.  
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Table 1. Baseline characteristics  
Total  
N=275 
Age 70 (62-76) 
Gender 
 
   Male 223 (81) 
   Female 52 (19) 
Ethnicity 
 
   Caucasian 235 (85) 
   AA 6 (2) 
   Other 34 (12) 
Tobacco 
 
   No 29 (11) 
   Yes 149 (54) 
   Unknown 97 (35) 
Personal History of Other Cancers 
 
   No 148 (54) 
   Yes 52 (19) 
   Missing 75 (27) 
Procedure 
 
   TURBT 120 (44) 
   RC 136 (49) 
   Other 19 (7) 
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Table 2. Tumor and clinical characteristics - MAGE  MAGE and PD-L1 subgroups  
MAGE Neg MAGE Pos p-value  MN/PN MP/PN MN/PP MP/PP p-value 
Overall, n (%) 321 (76) 101 (23) 
 
 232 (55) 72 (17) 89 (21) 29 (7)  
Target Stage 
  
<0.001      <0.001 
   pTa 113 (36) 21 (21) 
 
 96 (42) 17 (24) 17 (19) 4 (14)  
   pTis 34 (11) 4 (4) 
 
 27 (12) 3 (4) 7 (8) 1 (3)  
   pT1 38 (12) 23 (23) 
 
 25 (11) 17 (24) 13 (15) 6 (21)  
   pT2 61 (19) 33 (33) 
 
 35 (15) 20 (28) 26 (30) 13 (45)  
   pT3-4 50 (16) 13 (13) 
 
 30 (13) 10 (14) 20 (23) 3 (10)  
   Metastasis 21 (7) 6 (6) 
 
 16 (7) 4 (6) 5 (6) 2 (7)  
Grade 
  
0.015      <0.001 
   Low 129 (40) 27 (27) 
 
 109 (47) 24 (33) 20 (22) 3 (10)  
   High 192 (60) 74 (73) 
 
 123 (53) 48 (67) 69 (78) 26 (90)  
Surgical margins 
  
0.92      0.72 
   Neg 130 (40) 42 (42) 
 
 90 (39) 29 (40) 40 (45) 13 (45)  
   Pos 13 (4) 3 (3) 
 
 10 (4) 1 (1) 3 (3) 2 (7)  
   Missing 178 (55) 56 (55) 
 
 132 (57) 42 (58) 46 (52) 14 (48)  
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3.2. MAGE outcomes 
The median follow-up time for the entire cohort was 77 months (IQR 22-118 months). The median 
RFS for MP samples was 32 months, while those who were MN did not reach median RFS. The 
5-year RFS in MP was 44% compared with 58% for MN samples (figure 1). On univariable cox 
model (table 3), MP was significantly associated with recurrence (HR 1.84, 95%CI 1.09-3.09; 
p=0.02), similarly on multivariable analysis adjusting for baseline and clinical variables, MP was 
also associated with shorter recurrence (HR 1.55, 95%CI 1.05-2.30; p=0.03). Model performance 
using Harrel’s C statistic was 0.64. Median follow-up for patients who underwent RC was 38 
months (IQR 13-101). The 5-year PFS in MP was 44% compared with 82% for MN samples 
(figure 1). On univariable analysis MP was also significantly associated with shorter PFS (HR 
3.12, 95%CI 1.12-8.68; p=0.03).  The median overall survival in patients who underwent RC and 
had MP staining was 46 months compared with 77 months in MN patients. In addition, 5-year OS 
was 44% vs 51% in MP vs. MN patients, respectively (figure 2). However, there was no association 
with OS in either the univariable (HR 1.15, 96%CI 0.71-1.87; p=0.56) or multivariable cox model 
(HR 1.01, 95%CI 0.58-1.75; p=0.97). Furthermore, in a sensitivity analysis, year of treatment did 
not influence OS. 
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Figure 1. Recurrence-free (A) progression-free (B) and overall survival (C) outcomes for 
MAGE-A staining (cutoff ≥50% positive staining with 2+/3+ intensity) 
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Figure 2. Recurrence-free (A) and overall survival (B) outcomes for MAGE-A (cutoff ≥50% 
positive staining with 2+/3+ intensity) and PD-L1 co-expression (cutoff ≥1% staining) 
 
 
 
b 
a 
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3.3. MAGE/PD-L1 outcomes 
There were 27% PD-L1 positive samples. Co-expression of MAGE and PD-L1 was assessed by 
categorizing samples in subgroups by staining result (table 2). A higher proportion of non-muscle 
invasive bladder cancer samples (65%) were negative for both MAGE and PD-L1, whereas, there 
was a significant trend towards higher stage disease (p=<0.001) for samples that were positive for 
either marker. In the MAGE positive/PD-L1 negative group, 48% were ≥pT2, whereas in the 
MAGE negative/PD-L1 positive and double MAGE and PD-L1 positive groups, the percentages 
were 59% and 62%, respectively. A similar trend was observed in high grade disease; 90% of 
samples that were positive for both MAGE and PD-L1 were high grade (p=<0.001), for example. 
On univariable analysis, overall PD-L1 positivity was not associated with shorter RFS (HR 0.79, 
95%CI 0.55-1.14; p=0.21). However, PD-L1 positivity was associated with shorter PFS (HR 5.31, 
95%CI 1.99-14.2 p=0.001) (table 4). MAGE positive/PD-L1 negative samples comprised a subset 
associated with a shorter median recurrence-free survival of 19 months (HR 1.96, 95%CI 1.30-
2.95; p=<0.001) (figure 2). Furthermore, when adjusting for clinical variables, this subset was still 
associated with shorter RFS (HR 1.89, 95%CI 1.19-2.99; p=0.006) (table 5). Model performance 
using Harrell’s C statistic resulted in an AUC of 0.65.  Of the associations observed, the most 
significant was the double-positive subset with shorter PFS (HR 17.1, 95%CI 5.96-49.4; 
p=<0.001). There was no difference in RFS among the other groups (table 4). OS was also not 
significant among the groups (figure 2).  
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4. Discussion 
 
The treatment of urothelial carcinoma has undergone major changes in recent years, namely the 
addition of immuno-oncology agents that have been shown to provide significant benefit in 
advanced disease. [19] While the excitement is warranted, curative therapies for advanced disease 
are lacking. Cancer-testis antigens (CTAs), specifically MAGE-A, have emerged as potential 
targets for immune-oncologic strategies in the setting of advanced cancers. The prognostic 
implication of MAGE-A expression has been established in numerous malignancies without 
evidence of expression in normal tissue. [20] In UC, a number of studies using different expression 
analyses have shown that a significant proportion of patients with UC have expression of MAGE-
A, and increased expression of MAGE-A was associated with shorter clinical outcomes. Dyrskjøt 
et al. have shown using an q-RT-PCR that 43% of MAGE-A expression was associated shorter 
Table 4. Progression-free survival model  
 Unadjusted  
HR (95% CI) p-value 
MAGE    
   Negative Ref.  
   Positive 3.12 (1.12-8.68) 0.03 
PD-L1   
   Negative Ref.  
   Positive 5.31 (1.99-14.2) 0.001 
Groups   
   MN/PN Ref.  
   MP/PN 4.16 (0.86-20.1) 0.08 
   MN/PP 6.62 (1.99-22.0) 0.002 
   MP/PP 17.1 (5.96-49.4) <0.001 
Table 5. Recurrence-free survival model – MAGE/PD-L1 
 Unadjusted Adjusted*  
HR (95% CI) p-value HR (95% CI) p-value 
Groups   
 
 
MN/PN Ref.  Ref.  
MP/PN 1.96 (1.30-2.95) 0.001 1.89 (1.19-2.99) 0.006 
MN/PP 0.88 (0.56-1.38) 0.57 0.96 (0.59-1.55) 0.86 
MP/PP 1.07 (0.58-1.99) 0.82 1.04 (0.52-2.07) 0.92 
* Adjusted for age, gender, race, smoking history, pathologic stage, grade, and margins. 
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progression-free survival (HR 2.96, 96%CI 1.14–7.68; p=0.026). [4] Similar expression profile of 
MAGE-A was shown using TMA in a large cohort, which was associated with shorter cancer-
specific survival in UC (HR 1.44, 95% CI 1.05–1.99, p=0.02). [6] In our study, using a more 
restrictive definition of MP in IHC samples, we found increased expression in 23%, which was 
significantly associated with shorter recurrence-free survival on both univariable and multivariable 
survival model. In addition, PFS was significantly shorter in MP group. In an exploratory analysis, 
we also found 43% MAGE-A expression using a less restrictive definition reported in previous 
studies. Furthermore, overall survival was not significantly different between MP and MN groups. 
This may be partly due to comorbidities or various treatments received that affect overall survival. 
 
The possibility of using a combination strategy to target tumors, unleashing the immune system 
by targeting MAGE positive tissue while simultaneously allowing the immune system to function 
unimpeded via PD-L1 blockade is an attractive one. [21]  Such  strategies are being evaluated in 
other malignancies and have shown a potentiated response in combination approach in mouse 
models, [11, 12] And, clinical trials using a combination of adoptive cell and checkpoint inhibitor 
therapy are underway (NCT03296137, NCT03287674, NCT03296137).  Thus, further exploration 
of MAGE and PD-L1 expression patterns in UC is warranted as a foundation for such combination 
approaches. In our secondary analysis, we explored the prognostic implications of both MAGE-A 
and PD-L1 expression, and whether it informs such a strategy in UC. To assess co-expression, we 
sub-categorized expression groups. The MAGE positive/PD-L1 negative group was associated 
with shorter RFS compared with the other expression groups. The MAGE and PD-L1 double-
positive group was significantly associated with shorter PFS, but was not associated with shorter 
RFS, despite the fact that 62% of samples in this group were ≥pT2 and 90% were high grade (table 
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2), features that would be expected to associate with recurrence. This may be partially explained 
by the fact that many recurrences may have occurred in lower stage patients, and MAGE-A and 
PD-L1 expression seems to be more prevalent in more advanced disease.  
 
The strengths of this study are first, the ability to look at a relatively large sample of UCs, while 
looking at the recurrence and progression outcomes in MAGE-A and PD-L1 expression. Second, 
to our knowledge, there are no studies looking at prognostic implications of the co-expression of 
MAGE-A and PD-L1 in UC. While it is unclear whether expression of MAGE-A will influence 
PD-L1 expression or vice versa, it is clinically relevant that there is a reasonable proportion of 
patients that simultaneously express MAGE and PD-L1 perhaps supporting a possible combination 
strategy. In addition, uniform TMA construction, staining and interpretation was done to reduce 
potential variability. The limitations of this study include its retrospective nature with many 
potential confounders and risk profile of each patient, such as performance status and treatments 
received, which may affect the results.  
 
5. Conclusion 
 
In this study, we demonstrate the association of MAGE-A IHC expression in UC with shorter 
recurrence and progression-free survival. Furthermore, co-expression of MAGE-A and PD-L1 are 
present in more advanced disease states, which translated into shorter PFS. This supports possible 
co-targeting of MAGE and PD-L1 strategy in advanced UC. Further study and validation of these 
findings are warranted. 
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6. APPENDICES  
6.1. Data Origin 
 
The tissue microarray was originally constructed from a historical database from 3 surgeons at 
UCLA between 1984-1998. Clinical data was entered on the individual patients as the database 
was kept prospectively. However, data was not entered fully. In addition, some important 
variables such was systemic therapy was not full 6recorded. However, the data is robust 
compared with other the concurrent literature and the number of samples for the TMA 
construction is robust for a meaningful analysis, and therefore, we decided to use this database 
and tissue to assess survival outcomes for MAGE and PD-L1 staining.  
 
6.2. Statistical Considerations 
 
6.2.1. Missing data 
Initially, the question of missing data needed to be addressed, as we had an important variable of 
systemic therapy was missing in >70% of the data set. The reason is multifactorial. One reason is 
that most patients were not advanced disease in which systemic therapy is not indicated. 
Furthermore, standard of care had changed overtime and thus there were many patients who did 
not receive modern regimen prior to 1990. Finally, there is high potential for data entry error 
present. In order to assess the effect of time on our data, we conducted a sensitivity analysis by 
creating a categorized variable of YEAR 1984-1990 and >1990 and compared the survival 
outcomes, which did not show a difference. Other missing data were reduced significantly by 
using patient charts to add missing data on age, gender, race, stage and death. Data on cancer-
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specific events was minimal, and we were unable to capture this data from prior records, which 
precluded the analysis of cancer-specific survival. After data entry there were still missing data, 
however at lower rate than prior to data cleaning. Missing data variables were included as 
separate variables in all models to adjust possible effects on the main outcomes. 
 
6.2.2. Data set-up 
 
The main challenge with TMA data is that there were multiple patients with multiple samples per 
surgical event, or multiple surgical events per patients. This presented a challenge regarding the 
analysis of this data. We initially attempted to use a multilevel hierarchal linear regression with 
level 1 as patient, and level 2 as the sample to assess the outcome of H-score, which was a 
numeric score for staining per sample. However, the model was not stable or easily interpreted as 
the H-score variable contained many values of 0, the linearity assumption was violated, as well 
as significant herteroskdasticity. In order to try to simplify the model, we attempted to categorize 
H-score to signify positive staining versus negative staining. We relied on prior publications for 
the definition of MAGE positive as well as PD-L1 positive staining based on percent and 
intensity of staining. Co-expression of MAGE and PD-L1 was assessed by grouping MN/PN, 
MP/PN, etc in order to evaluate the prognostic value of co-expression of MAGE and PD-L1 and 
whether this would inform a possible co-targeting strategy of MAGE and PD-L1 therapy. There 
was some thought to compare the continuous variable H-score between PD-L1 and MAGE 
however, there were multiple values of zero making a correlation more difficult. In addition, 
given that our definitions of positive vs. negative are becoming more commonly used in the 
literature, we felt that comparison using these definitions would yield meaningful results. 
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In order to further decrease the complexity of the data, multiple samples from one surgical event 
were averaged in order to have one data entry per surgical event. Patients also had multiple 
ancillary procedures coded (such as bowel resection, lymph-node dissection etc), which were 
categorized under the parent procedures of transurethral resection of bladder tumor, radical 
cystectomy and other (for procedures that did not fit the aforementioned defintions). 
Furthermore, patients had multiple similar surgical procedure (TURBT) or different procedures 
at different time points (TURBT followed by RC). The handling of procedure is described below 
for the survival analysis.  
 
6.2.3. Baseline characteristics 
 
Patient-level data was used to assess baseline characteristics including age, gender, race, 
smoking history, cancer history and procedure. For clinical characteristics, we decided to use 
sample-level data as it was felt that, for example, target stage made more sense to present on the 
sample level as a patient who had multiple procedures may have multiple different stages for 
each event thereby making difficult to describe a single stage per patient. We then compared 
staining groups (MP vs. MN and co-expression groups) using Fisher’s exact test as there were a 
number of cells that had values fewer than 5. Continuous data, mainly age, was compared using 
Kurskal-Wallis test as the variable was not normally distributed.  
6.2.4. Survival analysis 
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There were three main survival analyses done, recurrence-free, progression-free, and overall 
survival. The main challenge is to analyzing patient vs. sample-level data for recurrence. We 
decided to use sample-level data as the justification for this was that each surgical event, and 
staining, may inform possible future recurrence. For example, lower stage samples are known to 
recur frequently, and thus an initial surgical event with stage Ta, for example, may recurs on the 
next surgical event. The staining of the first event may inform possible future recurrences, and so 
we felt that this would give important information regarding this process. Similarly, for 
progression; Does a sample from a surgical event with a certain staining pattern predict a 
progression to a higher stage? However, for overall survival, there can only be one death event, 
and thus we used only patient-level data. Furthermore, this analysis was conducted in only 
patients who underwent radical cystectomy as those patients who will likely die of their disease. 
TURBT can be thought of more of a biopsy in lower stage disease and thus was not used for the 
purpose of overall survival.  
 
The analysis was conducted using sample-level data to assess survival using the Kaplan-Meir 
method and log-rank test. For recurrence and progression, we used a mixed-effects Cox-
regression model in order to assess the hazard ratio for univariable and multivariable analysis. 
The mixed-effects model was done in order to adjust for clustering of multiple samples per 
patient, and thus we introduced a mu term in the equation. Variables that were statistically 
significant in the univariable, as well as variables that were felt to be important clinically (such 
as stage and grade) were included in the multivariable model. We then assessed the 
proportionality of the models using Schoenfeld residuals and the assumption was not violated. 
Furthermore, to assess all model performance, we used Harrell’s C statistic, which resulted in a 
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reasonable value of 0.64-0.65 for the models. A similar procedure was done for the analysis of 
overall survival, however, we used the standard Cox-regression model, as a mixed-effects 
adjustment was not necessary given one event per patient.  
 
6.2.5. Additional results 
 
In order to assess agreement of sample-level and patient-level data we evaluated the number of 
patients who had multiple biopsies one of which was MP and one MN. We found that all patients 
who had multiple biopsies had agreement. In other words, patients who had one biopsy MN and 
had a subsequent biopsy that was also MN, and vice versa.  
 
In our progression-free survival analysis, we performed KM curve analysis on patient groups and 
is presented below. The log-rank test was statistically significant p=<0.001. 
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